Allos Therapeutics to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
06 6월 2008 - 8:00PM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical
company focused on developing and commercializing innovative small
molecule drugs for the treatment of cancer, today announced that
members of the Company�s senior management will present a corporate
overview at the Seventh Annual Needham & Company, LLC
Biotechnology and Medical Technology Conference in New York. The
Company�s presentation will take place at 11 a.m. (Eastern) on
Thursday, June 12, 2008. There will be a live webcast of the
presentation, which will be accessible through a link posted on the
Allos website home page and investor relations section. The webcast
will be available for replay on Allos� website through June 30,
2008. About Allos Therapeutics, Inc. Allos Therapeutics is a
biopharmaceutical company focused on developing and commercializing
innovative small molecule drugs for the treatment of cancer.�The
Company's lead product candidate, PDX (pralatrexate), is a novel
antifolate currently under evaluation in a pivotal Phase 2 (PROPEL)
trial in patients with relapsed or refractory peripheral T-cell
lymphoma. The PROPEL trial is being conducted under an agreement
reached with the U.S. Food and Drug Administration under its
special protocol assessment, or SPA process. The Company is also
investigating PDX in patients with non-small cell lung cancer and a
range of lymphoma sub-types. The Company's other product
candidate�is RH1, a targeted chemotherapeutic agent currently being
evaluated in a Phase 1 trial in patients with advanced solid tumors
or non-Hodgkin�s lymphoma (NHL). For additional information, please
visit the Company�s website at www.allos.com. Safe Harbor Statement
The anticipated presentation will contain forward-looking
statements that involve significant risks and uncertainties.
Additional information concerning these forward-looking statements
and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K for the year ended December 31, 2007 and in the
Company's other periodic reports and filings with the Securities
and Exchange Commission. The Company cautions investors not to
place undue reliance on the forward-looking statements contained in
the presentation. All forward-looking statements are based on
information currently available to the Company on the date thereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this presentation, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Allos Therapeutics, Inc. News Articles